IOVA Live signaler | Maksimer profitt med Getagraph.com

SELG 1734 min ago

@ $13.47

Utstedt: 3 mai 2024 @ 20:30

Avkastning: 1.23%

Forrige signal: mai 3 - 19:27

Forrige signal: Kjøp

Avkastning: 0.86 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):
Our systems believe the stock currently is overvalued by 1.63% compare to its pairs and should correct downwards.

Stats
Dagens volum	4.23M
Gjennomsnittsvolum	8.88M
Markedsverdi	3.81B
EPS	$0 ( 2024-02-28 )
Neste inntjeningsdato	( $-0.450 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.21
ATR14	$0.580 (4.26%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Vogt Frederick G	Buy	20 834	Common Stock
2024-04-15	Vogt Frederick G	Sell	8 851	Common Stock
2024-04-15	Vogt Frederick G	Sell	20 834	Restricted Stock Units
2024-04-15	Graf Finckenstein Friedrich	Buy	2 812	Common Stock
2024-04-15	Graf Finckenstein Friedrich	Sell	1 427	Common Stock

INSIDER POWER
94.67
Last 99 transactions
Buy: 13 607 426 \| Sell: 449 378

Korrelasjon (AI algo v.1.1b): Overvalued: -1.63% $13.38 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Volum Korrelasjon

Lang: 0.77 (moderate)

Kort: -0.96 (very strong negative)

Signal:(69) Neutral

Iovance Biotherapeutics Korrelasjon

10 Mest positive korrelasjoner
LRMR	0.94
EQ	0.933
CFLT	0.924
POWL	0.916
TARA	0.914
MACK	0.902
PXLW	0.902
CLBT	0.901
MEDP	0.9
KTCC	0.9

10 Mest negative korrelasjoner
SSRM	-0.916
BLKB	-0.911
DCRC	-0.91
SGLB	-0.908
AMRB	-0.9
CAR	-0.886
BIOL	-0.878
WTER	-0.874
CYAN	-0.874
EGAN	-0.868

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Iovance Biotherapeutics Korrelasjon - Valuta/Råvare

0.11
( neutral )

0.55
( weak )

0.00
( neutral )

-0.01
( neutral )

-0.63
( weak negative )

-0.61
( weak negative )

Iovance Biotherapeutics Økonomi

Annual	2023
Omsetning:	$1.19M
Bruttogevinst:	$-31.94M (-2 686.12 %)
EPS:	$-1.890

FY	2023
Omsetning:	$1.19M
Bruttogevinst:	$-31.94M (-2 686.12 %)
EPS:	$-1.890

FY	2022
Omsetning:	$0
Bruttogevinst:	$-21.14M (0.00 %)
EPS:	$-2.45

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.20

Financial Reports:

No articles found.

Iovance Biotherapeutics

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Sanntidsoppdatering for Iovance Biotherapeutics [IOVA]

Upcoming Earnings Alert